7月30日，康方生物盘中下跌3.29%，报92.5港元/股，成交额3.23亿港元。
消息面上，公司于7月26日公告向167名承授人授出360.35万份购股权，行使价99.50港元，同时向162名承授人授出164.85万个受限制股份单位。当前股价较行使价折让约7%，短期市场对潜在摊薄及激励效力的担忧形成情绪压力。此前公司因依沃西全球III期OS数据更新于7月23日大涨近6%后，已连续多个交易日回调。此外，生物科技板块今日整体承压，信达生物跌4.07%、科伦博泰生物跌5.39%、荣昌生物跌5.80%，板块性资金流出进一步放大个股跌幅。
康方生物是一家致力于研究、开发、生产及商业化抗体药物的公司，在研项目涵盖肿瘤、自身免疫及代谢性疾病等多个领域，核心产品包括依沃西（PD-1/VEGF双抗）等。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.